Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07029581 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 60 to 61
    • Eligibility criteria expanded, about 11 words
  2. Study sites: 59 to 60v16
  3. Study sites: 57 to 59v15
  4. Study sites: 56 to 57v14
  5. Study sites: 54 to 56
    • Study description expanded, about 3 words
    v13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 52 to 54v12
  2. Study sites: 49 to 52v11
  3. Study sites: 37 to 49v10
  4. Study sites: 27 to 37v9
  5. Study sites: 18 to 27v8
  6. Study sites: 13 to 18v7
  7. Study sites: 10 to 13v6
  8. Study sites: 8 to 10v5
  9. Start date changed from estimate of Aug 2025 to Aug 6, 2025v4
  10. Study sites: 2 to 8v3
  11. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 2025 to Aug 2025
    • Study sites: 0 to 2
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Trial Details
NCT Number NCT07029581
Lead Sponsor ACADIA Pharmaceuticals Inc.
Conditions
(from sponsor)		 Lewy Body Dementia Psychosis
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov